Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA).
about
Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model.The University of Texas Houston Stroke Registry (UTHSR): implementation of enhanced data quality assurance procedures improves data quality.Who does it first? The uptake of medical innovations in the performance of thrombolysis on ischemic stroke patients in Germany: a study based on hospital quality data.Panaxatriol saponins attenuated oxygen-glucose deprivation injury in PC12 cells via activation of PI3K/Akt and Nrf2 signaling pathway.Evolution of the thrombolytic treatment window for acute ischemic stroke.Hyperbaric oxygen therapy in acute ischemic stroke: a review.Blood biomarkers in cardioembolic stroke.Thrombolytic therapy for acute ischemic stroke beyond three hours.A pragmatic approach using magnetic resonance imaging to treat ischemic strokes of unknown onset time in a thrombolytic trial.MicroRNAs in cerebral ischemia-induced neurogenesis.Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after strokeTranslating promising preclinical neuroprotective therapies to human stroke trials.Targeting nitric oxide in the subacute restorative treatment of ischemic strokeEarly administration of therapeutic anticoagulation following intravenous thrombolysis for acute cardiogenic embolic stroke caused by left ventricular thrombus: case report and topic reviewMedical gases for stroke therapy: summary of progress 2015-2016.Purification of serine protease from polychaeta, Lumbrineris nipponica, and assessment of its fibrinolytic activity.Exosomes in stroke pathogenesis and therapy.Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke.Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.Withania somnifera: a pre-clinical study on neuroregenerative therapy for stroke.Acute Ischemic Stroke After Moderate to Severe Traumatic Brain Injury: Incidence and Impact on Outcome.Utilization of Workflow Process Maps to Analyze Gaps in Critical Event Notification at a Large, Urban Hospital.A program for solving the brain ischemia problem.Neurological assessment scores in rabbit embolic stroke modelsThrombolysis in Real Time: Demonstration of Revascularization with Intravenous Thrombolysis Therapy in the CT Scanner.Withania somnifera Improves Ischemic Stroke Outcomes by Attenuating PARP1-AIF-Mediated Caspase-Independent Apoptosis.Anisocoria secondary to inadvertent contact with scopolamine patch.Covalent-display of an active chimeric-recombinant tissue plasminogen activator on polyhydroxybutyrate granules surface.Regulatory B cells in Experimental Stroke.Role of TRPM7 in cerebral ischaemia and hypoxia.Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases.Stroke treatment using intravenous and intra-arterial tissue plasminogen activator.Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.Body Weight Estimation for Dose-Finding and Health Monitoring of Lying, Standing and Walking Patients Based on RGB-D Data.Cerebral ischemia and neuroregeneration.Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system.Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy.Stroke code simulation benefits advanced practice providers similar to neurology residents
P2860
Q30446434-57C2C4DC-51C3-4162-A97F-246A62D5CE41Q30648249-3ACB6522-0455-4285-A059-587D37336F5EQ30884217-468FCA40-7E1B-44E6-A5B1-8A9AE30DD095Q33681841-3CF10B75-6C8F-4F6E-BEAE-219699539360Q33688138-5DC7A11E-63D5-4E2A-ACB2-F1F0DEE38ACCQ34299855-40E76DC1-60E9-4338-B1CF-DF15A1CCBCF5Q34362880-63CC4EB3-B0D4-4808-B9F9-2F6B7C07663EQ35552867-49C242A6-057A-4596-8720-2174F64553C5Q36299690-033A7BB6-35FB-4DFE-A0E1-0A2DE9F3B822Q37102334-9F719CC6-7C55-4F5D-883E-6B7C7A51C72BQ37666013-69CE8898-C632-4DD8-A871-D37FCD7B1FEDQ37868574-8DA530A3-BE12-4E0E-8903-37F900AFDA80Q38099859-39F388CF-2BD9-4867-8B98-E26D3D6049A5Q38362607-D1954780-995B-4A0F-A779-BEB4AA6DC4D5Q38651801-D77C788D-8FFA-4CBA-B3DE-07CEC449473AQ38712672-BD3223F7-F800-46F2-BD83-CF28F9ADB815Q38795614-5CD622E5-A8C8-4C6F-AA63-1345E77B63C8Q39065047-A28D19D2-97E0-4AB6-B3A8-0FACB740DE1BQ39199415-BA741FD3-E477-4697-B09C-8544E7C6387FQ39490615-818C600F-BE5A-4DF8-92EA-A5AC656220D5Q40161393-80B6F2FE-63F6-4DD2-ABD1-54C254F21301Q40211791-92B41CF4-4EAE-44D4-AE46-50A0219471ABQ40836652-516A754D-C631-42A0-AFAE-8A6256A0414FQ42106000-2063B7BC-6BDD-4920-A73B-5BB2FE0FCDF1Q44739074-E173E780-094A-4B7B-8ECE-E6379226439DQ46223528-770B2906-5BB2-40E0-B6BA-533277A85549Q47141641-074D24F2-BBD4-4035-BEC0-5001CDC07DA0Q47760520-24ED781E-BDDA-4E9C-94AA-AC3CCDFEA09DQ47875435-8D94C0CD-7177-4E04-BEAE-C2D3B60D5011Q48195180-C9209906-F771-4E4F-B201-2E8087C04C1CQ48229609-5678F4A4-AE3A-4738-99AF-BCF44C7B1F05Q48364529-2C514DDE-DD29-4A03-B1E1-4BF3C3662D94Q48619867-2144C198-338A-4203-8305-9B7860A453BEQ48862997-D4A353B5-3FDB-47BF-91DE-591A1D637EF2Q52563247-0EE10DDE-DD1C-4D8E-B15B-FEF6BB44E3C8Q52603055-B8F83DA5-050B-40CF-A669-6B1B9B35FB3BQ55044611-890A457C-FA90-4417-85F9-0BAE2FE4E636Q55551696-E2BE1B49-7AA6-4D9E-8A62-D27A2FD02A24Q57102947-3585CEDB-3A38-462E-BA8B-F99C3E31072C
P2860
Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Acute stroke therapy with tiss ...... and Drug Administration (FDA).
@en
Acute stroke therapy with tissue plasminogen activator
@nl
type
label
Acute stroke therapy with tiss ...... and Drug Administration (FDA).
@en
Acute stroke therapy with tissue plasminogen activator
@nl
prefLabel
Acute stroke therapy with tiss ...... and Drug Administration (FDA).
@en
Acute stroke therapy with tissue plasminogen activator
@nl
P2860
P356
P1433
P1476
Acute stroke therapy with tiss ...... and Drug Administration (FDA).
@en
P2093
Justin A Zivin
P2860
P356
10.1002/ANA.21750
P577
2009-07-01T00:00:00Z